Live search
TopFind is fetching the latest matches for your search.
We reviewed 7 live results for tocilizumab and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Medicine and Rheumatology.
Source: Samitivej Hospital
Description
An IL-6 inhibitor biologic DMARD used for rheumatoid arthritis and systemic juvenile idiopathic arthritis. It is available as an 80 mg/4 ml sterile solution and may require prior authorization for reimbursement in certain Thai health schemes.
Best for
IL-6 inhibitor therapy, juvenile idiopathic arthritis, advanced RA treatment and specialized biologic access
Rating
Source: Celltrion, Inc.
Description
AVTOZMA is an FDA and EC approved biosimilar to Actemra (tocilizumab), functioning as an IL-6 receptor antagonist. It is indicated for treating inflammatory conditions including rheumatoid arthritis (RA), giant cell arteritis (GCA), and polyarticular and systemic juvenile idiopathic arthritis. The product is available in both intravenous (IV) infusion and subcutaneous (SC) injection formats, including prefilled syringes and autoinjectors. For more information, visit https://www.avtozma.com.
Best for
rheumatoid arthritis patients, biosimilar medication preference, IL-6 receptor inhibition therapy and subcutaneous injection users
Rating
Source: Biogen
Description
Tofidence is a tocilizumab biosimilar developed for intravenous administration. It is FDA-approved for indications including Rheumatoid Arthritis (RA), Polyarticular Juvenile Idiopathic Arthritis (pJIA), and Systemic Juvenile Idiopathic Arthritis (sJIA). As a biosimilar, it aims to provide a high-quality, clinical equivalent to the originator product to improve patient access to biologic therapy.
Best for
Cost-effective biologic therapy, IV infusion therapy, Rheumatoid arthritis patients and US market access
Rating
| Compare | Tocilizumab | AVTOZMA® (tocilizumab-anoh) | Tofidence |
|---|---|---|---|
| Source | Samitivej Hospital | Celltrion, Inc. | Biogen |
| Description | An IL-6 inhibitor biologic DMARD used for rheumatoid arthritis and systemic juvenile idiopathic arthritis. It is available as an 80 mg/4 ml sterile solution and may require prior authorization for reimbursement in certain Thai health schemes. | AVTOZMA is an FDA and EC approved biosimilar to Actemra (tocilizumab), functioning as an IL-6 receptor antagonist. It is indicated for treating inflammatory conditions including rheumatoid arthritis (RA), giant cell arteritis (GCA), and polyarticular and systemic juvenile idiopathic arthritis. The product is available in both intravenous (IV) infusion and subcutaneous (SC) injection formats, including prefilled syringes and autoinjectors. For more information, visit https://www.avtozma.com. | Tofidence is a tocilizumab biosimilar developed for intravenous administration. It is FDA-approved for indications including Rheumatoid Arthritis (RA), Polyarticular Juvenile Idiopathic Arthritis (pJIA), and Systemic Juvenile Idiopathic Arthritis (sJIA). As a biosimilar, it aims to provide a high-quality, clinical equivalent to the originator product to improve patient access to biologic therapy. |
| Best for | IL-6 inhibitor therapy, juvenile idiopathic arthritis, advanced RA treatment and specialized biologic access | rheumatoid arthritis patients, biosimilar medication preference, IL-6 receptor inhibition therapy and subcutaneous injection users | Cost-effective biologic therapy, IV infusion therapy, Rheumatoid arthritis patients and US market access |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
If you want the most balanced option to start with, I recommend:
"Tocilizumab from Samitivej Hospital."
I picked this because A specialized biologic therapy suitable for adult RA and systemic juvenile idiopathic arthritis cases.